OncoCyte Corporation
http://www.oncocyte.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OncoCyte Corporation
Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Financing Quarterly Statistics, Q2 2022
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
Merck & Co. Looks To Artiva’s Off-The-Shelf Cell Therapy Technologies
Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- BioTime, Inc.
- Chronix Biomedical
- Insight Genetics
- Razor Genomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice